Clinical trials: Hypopharyngeal Neoplasms
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Head and Neck Cancer
Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00005087
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 235 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer
Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00608205
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Head and Neck Cancer
Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- CAPRA (NCT01333085)
- Testing
- carboplatin, RAD001, paclitaxel
- Where
- 5 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
This phase II clinical trial studies how well soy isoflavones work in preventing head and neck cancer in patients with stage I-IV head and neck cancer undergoing surgery.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02007200
- Testing
- Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00011999
- Testing
- cisplatin, paclitaxel, conventional surgery
- Where
- 234 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Cancer, Mucositis
Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer
RATIONALE: Growth factors, such as palifermin, may lessen the severity of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
- Trial name
- NCT00360971
- Testing
- palifermin, cisplatin, neck dissection
- Where
- 48 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Radiation Therapy Oncology Group
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma
Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
This phase II trial studies how well nivolumab, carboplatin, and paclitaxel work in treating patients with stage III-IV head and neck squamous cell carcinoma that can be removed by surgery.
- Conditions
- Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT03342911
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Head & Neck Cancer
Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical study aimed to evaluate the efficacy and safety of penpulimab combined with chemotherapy in the treatment of locally advanced hypopharyngeal carcinoma.
- Trial name
- NCT07752394
- Testing
- Finotonlimab, Nab-paclitaxel, carboplatin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tang-Du Hospital
Hypopharyngeal Cancer
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
Hypopharyngeal cancer is an important part of head and neck cancer, with more than 80,000 new cases in 2018. And it is a highly aggressive cancer often diagnosed at an advanced stage.
- Trial name
- NCT04502641
- Testing
- Docetaxel, 5-fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Acute Pain
Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
Patient satisfaction with healthcare is increasingly being utilized as a metric to reflect provider and hospital quality of care.
- Conditions
- Head and Neck Cancer, Acute Pain, Postoperative Pain
- Trial name
- GABA (NCT02926573)
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004094
- Testing
- carboplatin, fluorouracil, hydroxyurea
- Where
- 4 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
This phase I trial studies the side effects and best dose of onalespib when given together with intensity-modulated radiation therapy (IMRT) and cisplatin in treating patients with squamous cell carcinoma of the head and neck…
- Conditions
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Trial name
- NCT02381535
- Testing
- Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 2 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This randomized phase II trial studies how well cisplatin with or without WEE1 inhibitor MK-1775 works in treating patients with head and neck cancer that has come back or has spread to other parts of the body.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02196168
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma, Pharyngocutaneous Fistula
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
Investigators performing this research want to look at the use of a special imaging process during a specific throat surgery. Using this imaging may help to lower a common complication that called a pharyngocutaneous fistula…
- Trial name
- NCT06831149
- Testing
- Removal of pharyngeal mucosa with decreased perfusion will be performed, SPY-PHI, ICG (Indocyanine Green)
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Matthew Spector
Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
This phase I trial studies the side effects and best dose of giving everolimus (RAD001) and erlotinib hydrochloride together with radiation therapy in treating patients with recurrent head and neck cancer previously treated with…
- Conditions
- Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT01332279
- Testing
- everolimus, erlotinib hydrochloride, biopsy
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Oropharynx
Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients
Oral mucositis remains a limiting factor in in head and neck squamous cell carcinomas patients treated with chemoradiation leading to pain, dysphagia, and weight loss.
- Conditions
- Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of Hypopharynx
- Trial name
- NCT01439724
- Testing
- Low Level Laser Therapy- (DMC, São Paulo, Brazil)
- Where
- Brazil
- Volunteers
- 94 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Head and Neck Cancer
Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal lurtotecan in treating patients who have…
- Trial name
- NCT00022594
- Testing
- liposomal lurtotecan
- Where
- 20 sites in Austria, Belgium and 8 more
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC